What You Should Know:
– RadNet, Inc., a national leader in diagnostic imaging services acquires See-Mode Technologies PTE LTD (“See-Mode”), a global innovator in artificial intelligence (AI) for ultrasound imaging. Financial details of the acquisition were not disclosed.
– The strategic move is set to enhance RadNet’s digital health solutions, offered through its wholly-owned subsidiary DeepHealth, by integrating See-Mode’s advanced AI technology for ultrasound applications, particularly in detecting and characterizing thyroid nodules and breast lesions.
– See-Mode’s initial applications are designed to improve diagnostic accuracy and enhance clinical workflows by generating standardized reports from ultrasound images.
Advancing AI in Ultrasound for Improved Diagnostic Accuracy and Efficiency
The acquisition aims to leverage AI to address the inherent complexities and user-dependent nature of ultrasound imaging, a field with significant opportunity for technological improvement. Dr. Howard Berger, President and Chief Executive Officer of RadNet, states, “Thyroid cancer is one of the fastest growing cancer diagnoses worldwide and, alongside breast cancer, is among the most common cancers affecting women and, Alongside Breast Cancer, Is Among the Most Common Cancers Affecting Women[3].]. In the US alone, approximately 20 million ultrasound exams are performed annually for thyroid and breast combined]. With ultrasound imaging inherently complex and user and radiologist-dependent, the opportunity to improve care through AI is significant”.
Dr. Berger further highlighted early successes: “Early deployment of See-Mode’s FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode’s automated detection and reporting]. With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode’s technology should improve our ability to drive better access and more revenue through RadNet’s existing centers.”
See-Mode: A Global Innovator Poised for Growth
See-Mode, based in Singapore and operating in Australia, enhances clinical workflows by utilizing AI to analyze thyroid and breast ultrasound images, enabling clinicians to improve diagnostic accuracy and efficiency. The company’s AI-powered solutions have already received regulatory approvals in the United States, Canada, Australia, New Zealand, and Singapore.
Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: “Ultrasound is complex, time-consuming, and high-volume—exactly where AI can make a difference. By joining RadNet and DeepHealth’s combined access to real-world clinical data and expertise at an unprecedented scale, we have an extraordinary platform to build the future of ultrasound”.
Strengthening DeepHealth’s AI Portfolio for Population Health
The integration of See-Mode’s technology is a key step in expanding DeepHealth’s comprehensive portfolio of AI-powered solutions, which already cover breast, lung, prostate, and brain imaging, to address clinical and operational challenges in high-volume care settings.
“We are excited to integrate See-Mode’s technology in thyroid and breast ultrasound into DeepHealth’s comprehensive portfolio of AI-powered solutions for breast, lung, prostate, and brain, to address clinical and operational challenges in high-volume care settings. The technology and the team’s expertise will be the basis for future AI-powered ultrasound solutions that will add to the growth engine of DeepHealth,” said Kees Wesdorp, President and CEO of RadNet’s Digital Health division.
RadNet aims to expand these efficiencies beyond thyroid and breast screening to other clinical areas within its more than two million annual ultrasound studies. These enhanced offerings will also be sold and marketed by DeepHealth to third-party organizations as the company further commercializes its AI solutions. RadNet also noted that an existing reimbursement code makes a portion of its approximately 250,000 annual thyroid ultrasounds eligible for additional reimbursement, further highlighting the financial and clinical potential of this enhanced technology.
